Neuraxpharm Group
Manufacturing · Germany · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
Elisabeth-selbert-str. 23, Langenfeld, N...Phone Number
+44 1189654073Website
www.neuraxpharm.comRevenue
$546.4 MillionIndustry
About Neuraxpharm Group
Neuraxpharm Group Org Chart
Is Neuraxpharm Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Neuraxpharm Group had a recent Job posting/layoffs
Check if Neuraxpharm Group has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Neuraxpharm Group
Funding: Get notified immidiatlly once Neuraxpharm Group has new funding data
Check out if Neuraxpharm Group is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Neuraxpharm Group launches new products
Neuraxpharm Group, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Neuraxpharm Group recently announced quarterly report
Recommended Actions
Find VP level buyers at Neuraxpharm Group
Find more new buyers
Company Profile Activity
Activity Insights
Neuraxpharm Group is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neuraxpharm Group is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neuraxpharm Group.
Neuraxpharm Group Tech Stack
A closer look at the technologies used by Neuraxpharm Group
Most Recent Scoops
Neuraxpharm Group News & Media
Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures
A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real time, alerting patients and caregivers minutes before an episode occurs1 This breakthrough innovation represents a major milestone in Neuraxpharm's...Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis
BARCELONA, Spain and DÜSSELDORF, Germany, Sept. 22, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, is participating in the 41st Congress of the European Committee for...Neuraxpharm continues international expansion with launch of Neuraxpharm Australia
Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil® (modafinil), and bring BRIUMVI® (ublituximab) to patients in Australia SYDNEY and...Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson's Disease
Infudopa SubC® is a user-friendly and minimally invasive alternative enabling flexible dosing and thereby empowering patients with greater independence DÜSSELDORF, Germany and GOTHENBURG, Sweden, July 8, 2025 /PRNewswire/ -- Neuraxpharm Group ("Neuraxpharm"), a leading European specialty...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neuraxpharm Group
Founded in 1985 and headquartered in Germany, Neuraxpharm Group is a leading European specialty pharmaceutical company in the treatment of central nervous system disorders (CNS). The company offers a wide range of proven, differentiated and affordable CNS treatment options to patients, healthcare professionals and industry partners.... Read More